Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Collins

Showing results (161-170 of 247) with videos related to

Pageof 25
Sort By:
Journal of Virology|February 14, 2006
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challengeAlexander Bukreyev, Lijuan Yang, Sherif R Zaki, et al.
Human Gene Therapy|August 26, 2010
α-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectorsLiqun Zhang, Maria P Limberis, Catherine Thompson, et al.
Journal of Virology|January 30, 2004
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitroJosephine M McAuliffe, Sonja R Surman, Jason T Newman, et al.
Journal of Virology|March 28, 2014
Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapyKevin B Walsh, John R Teijaro, Linda G Brock, et al.
Plos One|January 4, 2013
Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strainSa Xiao, Baibaswata Nayak, Arthur Samuel, et al.
Journal of Virology|January 31, 2014
Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infectionBo Liang, Shirin Munir, Emerito Amaro-Carambot, et al.
Journal of Virology|February 11, 2011
Both nonstructural proteins NS1 and NS2 of pneumonia virus of mice are inhibitors of the interferon type I and type III responses in vivoBritta Heinze, Stefanie Frey, Markus Mordstein, et al.
Journal of Virology|February 4, 2011
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primatesAnne Schaap-Nutt, Caraline Higgins, Emerito Amaro-Carambot, et al.
Plos One|February 12, 2020
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidatesXueqiao Liu, Bo Liang, Xiang Liu, et al.
Plos One|March 14, 2022
Correction: Generation by Reverse Genetics of an Effective, Stable, Live-Attenuated Newcastle Disease Virus Vaccine Based on a Currently Circulating, Highly Virulent Indonesian StrainSa Xiao, Baibaswata Nayak, Arthur Samuel, et al.
Pageof 25

Showing results (161-170 of 247) with videos related to

Sort By:
Pageof 25
Journal of Virology|February 14, 2006
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challengeAlexander Bukreyev, Lijuan Yang, Sherif R Zaki, et al.
Human Gene Therapy|August 26, 2010
α-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectorsLiqun Zhang, Maria P Limberis, Catherine Thompson, et al.
Journal of Virology|January 30, 2004
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitroJosephine M McAuliffe, Sonja R Surman, Jason T Newman, et al.
Journal of Virology|March 28, 2014
Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapyKevin B Walsh, John R Teijaro, Linda G Brock, et al.
Plos One|January 4, 2013
Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strainSa Xiao, Baibaswata Nayak, Arthur Samuel, et al.
Journal of Virology|January 31, 2014
Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infectionBo Liang, Shirin Munir, Emerito Amaro-Carambot, et al.
Journal of Virology|February 11, 2011
Both nonstructural proteins NS1 and NS2 of pneumonia virus of mice are inhibitors of the interferon type I and type III responses in vivoBritta Heinze, Stefanie Frey, Markus Mordstein, et al.
Journal of Virology|February 4, 2011
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primatesAnne Schaap-Nutt, Caraline Higgins, Emerito Amaro-Carambot, et al.
Plos One|February 12, 2020
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidatesXueqiao Liu, Bo Liang, Xiang Liu, et al.
Plos One|March 14, 2022
Correction: Generation by Reverse Genetics of an Effective, Stable, Live-Attenuated Newcastle Disease Virus Vaccine Based on a Currently Circulating, Highly Virulent Indonesian StrainSa Xiao, Baibaswata Nayak, Arthur Samuel, et al.
Pageof 25